We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 03, 2022

Patient-Reported Outcomes of Trastuzumab Deruxtecan vs Treatment of Physician's Choice in HER2-Low MBC

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
Ann. Oncol 2022 Sep 01;33(suppl 7)S632-S633, NT Ueno, W Jacot, T Yamashita, et al

Further Reading